Pegylated liposomal doxorubicin monotherapy (Kaposi sarcoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN |
|---|
| ID | REG-PLD-KAPOSI |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Notes
New Regimen entity reusing the existing DRUG-PEGYLATED-LIPOSOMAL- DOXORUBICIN Drug entity. The 20 mg/m² IV q2-3wk Kaposi sarcoma dose and toxicity-management triggers (hold thresholds for PPE, stomatitis, ANC/platelet nadir, LVEF decline) are transcribed directly from that ALREADY-EXISTING Drug entity's `typical_dosing`/`notes` fields (which independently document "Kaposi sarcoma: 20 mg/m² IV every 2-3 weeks" and the hold criteria -- verified by direct read of drugs/pegylated_liposomal_doxorubicin.yaml during independent review) -- not a newly invented figure. Pegylated liposomal doxorubicin is FDA-approved for AIDS-related Kaposi sarcoma (see DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN.regulatory_status.fda. indications_brief). INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 throughout this file (top-level sources, every dose-adjustment, every watchpoint) as the evidentiary support for the dosing/toxicity-management content above. Direct inspection of that source's own KB record (sources/src_nccn_skin_2025.yaml) shows its title is "NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer" and its notes explicitly scope it to basal-cell...
Used By
Disease
DIS-KAPOSI- Kaposi sarcoma
Indication
IND-KAPOSI-1L-VISCERAL-PLD- IND-KAPOSI-1L-VISCERAL-PLD